Baidu
map

CLIN CANCER RES:乳腺癌肝转移瘤PI3K-AKT-mTOR通路活性增强

2017-08-29 MedSci MedSci原创

乳腺癌特定转移部位的分子特征尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究PI3K-AKT-mTOR通路的改变或活化是否与乳腺癌特定转移部位有关。

乳腺癌特定转移部位的分子特征尚不清楚。CLIN CANCER RES近期发表了一篇文章,研究PI3K-AKT-mTOR通路的改变或活化是否与乳腺癌特定转移部位有关。

作者通过全基因组测序联合反相蛋白芯片技术(RPPA)对32例治疗前乳腺癌转移的患者进行功能信号分析,探索PI3K-AKT-mTOR轴所起到的作用。并进一步分析了154例乳腺癌转移部位和101例非匹配的原发乳腺癌组织的信号数据。比较肝脏和非肝脏部位的PI3K-AKT-mTOR改变或信号网络活力。研究表明,与非肝脏转移相比,肝转移的PIK3CA突变以及AKT和p70S6K活化频率更高。但是,PIK3CA突变单独不能有效预测蛋白活化。含有154例肿瘤的独立队列的RPPA分析确认了通路活化与肝转移之间的关系。肝转移和原发乳腺癌之间也能观察到相似结果。当原发肿瘤与所有转移部位联合比较时,这一联系便消失了。

文章最后得出结论,乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关。

原始出处:
Mariaelena Pierobon,Corinne Ramos,et al.Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.CLIN CANCER RES.August 2017.doi:10.1158/1078-0432.CCR-16-2656

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2076055, encodeId=e20420e60555e, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Wed Sep 13 13:40:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656155, encodeId=bc2f165615588, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Thu Aug 31 23:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333191, encodeId=de5213331911c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443814, encodeId=9c96144381478, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238788, encodeId=9ac9238e888c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 23:03:35 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238425, encodeId=866a238425ff, content=乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Aug 29 20:38:07 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2076055, encodeId=e20420e60555e, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Wed Sep 13 13:40:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656155, encodeId=bc2f165615588, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Thu Aug 31 23:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333191, encodeId=de5213331911c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443814, encodeId=9c96144381478, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238788, encodeId=9ac9238e888c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 23:03:35 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238425, encodeId=866a238425ff, content=乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Aug 29 20:38:07 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-31 xfpan20
  3. [GetPortalCommentsPageByObjectIdResponse(id=2076055, encodeId=e20420e60555e, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Wed Sep 13 13:40:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656155, encodeId=bc2f165615588, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Thu Aug 31 23:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333191, encodeId=de5213331911c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443814, encodeId=9c96144381478, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238788, encodeId=9ac9238e888c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 23:03:35 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238425, encodeId=866a238425ff, content=乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Aug 29 20:38:07 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2076055, encodeId=e20420e60555e, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Wed Sep 13 13:40:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656155, encodeId=bc2f165615588, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Thu Aug 31 23:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333191, encodeId=de5213331911c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443814, encodeId=9c96144381478, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238788, encodeId=9ac9238e888c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 23:03:35 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238425, encodeId=866a238425ff, content=乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Aug 29 20:38:07 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2076055, encodeId=e20420e60555e, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Wed Sep 13 13:40:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656155, encodeId=bc2f165615588, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Thu Aug 31 23:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333191, encodeId=de5213331911c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443814, encodeId=9c96144381478, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238788, encodeId=9ac9238e888c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 23:03:35 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238425, encodeId=866a238425ff, content=乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Aug 29 20:38:07 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 luominglian113

    学习了.谢谢分享

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2076055, encodeId=e20420e60555e, content=<a href='/topic/show?id=8a3b93455ec' target=_blank style='color:#2F92EE;'>#转移瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93455, encryptionId=8a3b93455ec, topicName=转移瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3eaf430, createdName=bsmagic9132, createdTime=Wed Sep 13 13:40:00 CST 2017, time=2017-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1656155, encodeId=bc2f165615588, content=<a href='/topic/show?id=f4782246ec' target=_blank style='color:#2F92EE;'>#Akt#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2246, encryptionId=f4782246ec, topicName=Akt)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c724776724, createdName=xfpan20, createdTime=Thu Aug 31 23:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333191, encodeId=de5213331911c, content=<a href='/topic/show?id=ecfa1423117' target=_blank style='color:#2F92EE;'>#PI3K#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14231, encryptionId=ecfa1423117, topicName=PI3K)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/BF4BC9769C2FF12AC93CAA0069C0696C/100, createdBy=7bb22500091, createdName=ms1292405679162969, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443814, encodeId=9c96144381478, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Thu Aug 31 10:40:00 CST 2017, time=2017-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238788, encodeId=9ac9238e888c, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Wed Aug 30 23:03:35 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238425, encodeId=866a238425ff, content=乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关., beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Tue Aug 29 20:38:07 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 有备才能无患

    乳腺癌患者肝转移可能与PIK3CA突变频率增加及PI3K-AKT-mTOR信号通路活化有关.

    0

相关资讯

Eur Radiol:3D ABUS与HHUS在乳腺癌病变和BI-RADS特征显示的价值

现在,很多医院的乳腺钼靶片、B超检查和磁共振检查报告诊断为乳腺改变BI-RADS多少级,引起一些女性的无谓紧张,认为2级、3级就是癌症可能的2期、3期。其实,BI-RADS(Breast imaging reporting and data system)即美国放射学会推荐的"乳腺影像报告和数据系统"。本研究旨在评价自动乳腺超声(ABUS)与手持传统超声(HHUS)在显示乳腺病变和BI-RADS特

ESC大会:接受他汀类药物治疗的女性更不容易得乳腺癌?

对一百多万人进行了14年的研究发现,高胆固醇患者乳腺癌发病率明显降低,死亡率提高。在ESC大会上提出的研究表明,他汀类药物与乳腺癌的发生率和随后的死亡率相关。

Environmental Health Perspectives:光明下的肿瘤帮凶:夜间光照暴露增加患乳腺癌风险?

随着科技和生活的进步,越来越多的人生活在霓虹灯下的“不夜城”。可你是否会想到光照竟是恶性肿瘤的无形帮凶?可见光,顾名思义,是电磁波谱中人眼可以感知的部分,故而并不包括X光或其他损伤皮肤的紫外线。传统意义上,有害物质是剂量相关的:少而致伤,多可致毒。而可见光暴露的毒性无疑挑战着我们对于有毒物质的传统定义。可见光对人体健康的损害极其依赖于暴露的发生时间、而非所有的累积时间长度。百万年来,人类已经进化形

Eur Radiol:基于T2加权脂肪抑制和扩散加权 MRI的放射学分析在术前预测乳腺癌前哨淋巴结转移的价值

前哨淋巴结是原发肿瘤引流区域淋巴结中的特殊淋巴结,是原发肿瘤发生淋巴结转移所必经的第一批淋巴结。前哨淋巴结作为阻止肿瘤细胞从淋巴道扩散的屏障,其临床意义已受到人们的重视。本研究旨在预测基于T2加权脂肪抑制(T 2-FS)和扩散加权 MRI(DWI)的放射学分析在术前预测乳腺癌前哨淋巴结(SLN)转移的价值,并将结果发表在Eur Radiol上。

湖南一乳腺癌患者偏方“自救”,肿瘤变成皮球大小才去医院

8月24日,岳阳市中医院,36岁的谢雨梦躺在病床上,等待着切片结果。右侧乳房上巨大的肿瘤成了她的噩梦。近一年半的时间,肿瘤从花生米大小变成皮球大小,甚至溃烂、发臭、长蛆。她寻求过多种方法自救——服用偏方、吃“素食”,甚至被人使用放血疗法。唯一没做的,就是去正规医院治疗。直到奄奄一息,她才同意去医院寻求手术治疗。医生给她的答复是:来晚了。自救偏方、素食,成为她寻求治愈的方法事实上,从2016年3

CLIN CANCER RES:乳腺癌新辅助化疗过程中的转录反应

化疗导致的基因表达改变是由于肿瘤细胞转录重编或对于治疗的亚克隆适应。CLIN CANCER RES近期发表了一篇文章,研究对全转录组mRNA表达的影响,评估新辅助化疗联合贝伐单抗的治疗效果。

Baidu
map
Baidu
map
Baidu
map